## CITATION REPORT List of articles citing

Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression

DOI: 10.1111/apt.12914 Alimentary Pharmacology and Therapeutics, 2014, 40, 955-65

Source: https://exaly.com/paper-pdf/59053060/citation-report.pdf

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
114	Editorial: proton pump inhibitor-responsive oesophageal eosinophilia - two different phenotypes?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 485-7	6.1	O
113	Eosinophilic oesophagitis: a systematic review for otolaryngologists. <b>2015</b> , 129, 1156-66		2
112	Acid suppression therapy and allergic reactions. <b>2015</b> , 24, 25-33		O
111	Acid suppression therapy and allergic reactions. <b>2015</b> , 24, 303-311		12
110	Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 231-8	6.1	27
109	Proton pump inhibitor-responsive oesophageal eosinophilia and eosinophilic oesophagitis: more similarities than differences. <b>2015</b> , 31, 309-15		24
108	Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. <b>2015</b> , 12, 379-386		47
107	Esophageal Food Impaction and Eosinophilic Esophagitis: A Retrospective Study, Systematic Review, and Meta-Analysis. <b>2015</b> , 60, 3181-93		35
106	Eosinophilic esophagitis in adults: A distinct form of food allergy. <b>2015</b> , 55, 438-443		1
105	Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis. <b>2015</b> , 29, 749-7	758	21
104	Proton Pump Inhibitor Therapy in Eosinophilic Esophagitis: Current Role and Future Perspectives. <b>2015</b> , 2, 90-99		1
103	Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches. <b>2015</b> , 9, 1359-69		2
102	Dysphagia and health-related quality of life in patients with eosinophilic esophagitis: a long-term follow-up. <b>2015</b> , 272, 3833-9		9
101	Clinical features of Eosinophilic esophagitis in children and adults. <b>2015</b> , 29, 739-748		24
100	Eosinophilic Esophagitis. <b>2015</b> , 373, 1640-8		264
99	Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 776-84	6.1	29
98	Editorial: Is eosinophilic oesophagitis different to proton pump inhibitor-responsive oesophageal eosinophilia?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1023-4	6.1	2

## (2016-2015)

97	Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. <b>2015</b> , 110, 1567-75		78
96	[Proton Pump Inhibitor-responsive Esophageal Eosinophilia: An Overview of Cases from One University Hospital Center]. <b>2016</b> , 67, 178-82		4
95	Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 189-97	6.1	16
94	Oesophageal narrowing on barium oesophagram is more common in adult patients with eosinophilic oesophagitis than PPI-responsive oesophageal eosinophilia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1168-77	6.1	18
93	Combining different therapeutic interventions in eosinophilic esophagitis may lead to unreplicable and misleading results. <b>2016</b> , 29, 1172		1
92	High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia. <b>2016</b> , 62, 704-10		57
91	The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 534-40	6.1	43
90	Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. <b>2016</b> , 14, 179		181
89	The role of proton pump inhibitor therapy in the management of eosinophilic esophagitis. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 945-52	5.1	8
88	Editorial: management of eosinophilic oesophagitis - efficacy vs. effectiveness. AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 199-200	6.1	
87	The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 522-30	6.1	27
86	Lack of compliance with consensus recommendations on the diagnosis of eosinophilic esophagitis (EoE) in published prevalence studies. A clinical and systematic review. <b>2016</b> , 17, 660-669		5
85	Eosinophilic esophagitis: current perspectives from diagnosis to management. <b>2016</b> , 1380, 204-217		5
84	Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. <b>2016</b> , 137, 631-3		44
83	Proton pump inhibitor-responsive esophageal eosinophilia: A new entity in search of recognition?. <b>2016</b> , 81, 113-115		
82	Proton pump inhibitor-responsive esophageal eosinophilia: A new entity in search of recognition?. <b>2016</b> , 81, 113-5		4
81	Prevalence of allergic rhinitis and asthma in patients with chronic rhinosinusitis and gastroesophageal reflux disease. <b>2016</b> , 117, 158-162.e1		15
80	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. <b>2016</b> , 65, 524-31		219

79	Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. <b>2016</b> , 14, 13-22.e1		172
78	Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis. <b>2016</b> , 137, 931-4.e2		39
77	Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients. <b>2017</b> , 52, 203-210		29
76	Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. <b>2017</b> , 5, 335-358		437
75	Proton pump inhibitor-responsive esophageal eosinophilia: still a valid diagnosis?. <b>2017</b> , 33, 285-292		19
74	Management of Eosinophilic Esophagitis Based on Pathophysiological Evidence. <b>2017</b> , 51, 659-668		O
73	The Endoscopic Reference Score shows modest accuracy to predict either clinical or histological activity in adult patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 300-309	.1	27
72	Functional dyspepsia and duodenal eosinophilia: A new model. <b>2017</b> , 18, 667-677		19
71	GERD and Eosinophilic Esophagitis. <b>2017</b> , 227-236		
70	Eosinophilic esophagitis. The North against the South? A bio-economic-social mechanistic approach and clinical implications. <b>2017</b> , 82, 328-336		
69	Eosinophilic esophagitis. The North against the South? A bio-economic-social mechanistic approach and clinical implications. <b>2017</b> , 82, 328-336		4
68	Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: A Paradigm Shift. <b>2017</b> , 112, 1770-1773		21
67	Absence of esophageal eosinophilia in a toddler with severe eosinophilic esophagitis. 2017, 7, 243-246		
66	Functional Dyspepsia: Advances in Diagnosis and Therapy. <b>2017</b> , 11, 349-357		65
65	Low Prevalence of Biopsy-Proven Eosinophilic Esophagitis in Patients with Esophageal Food Impaction in Mexican Population. <b>2018</b> , 63, 1506-1512		2
64	Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy. <b>2018</b> , 33, 1016-1022		13
63	Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach. <b>2018</b> , 177, 649-663		23
62	Eosinophilic Esophagitis: Latent Disease in Patients with Anaphylactic Reaction to Cowß Milk. <b>2018</b> , 6, 451-456.e1		8

## (2019-2018)

61	Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007-2016). <b>2018</b> , 6, 29-37	23
60	Therapy with omeprazole modulates regulatory T cell/T helper 17 immune response in children with duodenal ulcers. <b>2018</b> , 26, 337-347	O
59	Esophagitis unrelated to reflux disease: current status and emerging diagnostic challenges. <b>2018</b> , 472, 29-41	3
58	Diagnosis and Management of Eosinophilic Esophagitis. <b>2018</b> , 38, 125-139	4
57	Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. <b>2018</b> , 8, e20	12
56	Respiratory symptoms associated with eosinophilic esophagitis. <b>2018</b> , 53, 1587-1591	9
55	Eosinophilic Esophagitis: Review and Update. <b>2018</b> , 5, 247	26
54	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <b>2018</b> , 155, 1022-1033.e10	367
53	Eosinophilic esophagitis: latest insights from diagnosis to therapy. <b>2018</b> , 1434, 84-93	14
52	Emerging drugs for eosinophilic esophagitis. <b>2018</b> , 23, 173-183	5
51	The Role of Proton Pump Inhibitors in the Management of Pediatric Eosinophilic Esophagitis. <b>2018</b> , 6, 119	8
50	Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. <b>2018</b> , 6, 1483-1495	15
49	RNA sequencing confirms similarities between PPI-responsive oesophageal eosinophilia and eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 219-225	5
48	Incidence and prevalence of eosinophilic oesophagitis increase continiously in adults and children in Central Spain: A 12-year population-based study. <b>2019</b> , 51, 55-62	21
47	Tangible pathologies in functional dyspepsia. <b>2019</b> , 40-41, 101650	11
46	The Predictive Factors of Responsiveness to Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis. <b>2019</b> , 1, 220-230	1
45	Eosinophilic Esophagitis Is Rarely Continually Symptomatic 10[Years After an Initial Treatment Course in Adults. <b>2019</b> , 64, 3568-3578	3
44	Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment. <b>2019</b> , 68, 420-429	33

43	Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. <b>2019</b> , 13, 99-117	18
42	Integration of a clinical scoring system in the management of eosinophilic esophagitis. 2020, 8, 786-789.e2	O
41	Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies.  Expert Review of Clinical Immunology, <b>2020</b> , 16, 63-77  5.1	7
40	Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. <b>2020</b> , 292, 84-89	4
39	Proton Pump Inhibitor Therapy in Eosinophilic Esophagitis: Predictors of Nonresponse. <b>2021</b> , 66, 3096-3104	1
38	Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians. <b>2020</b> , 14, 1069-1082	7
37	Eosinophilic esophagitis: updates on key unanswered questions. <b>2020</b> , 1481, 30-42	3
36	Subjective Symptoms in Patients with Eosinophilic Esophagitis Are Related to Esophageal Wall Thickness and Esophageal Body Pressure. <b>2021</b> , 66, 2291-2300	3
35	Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 798-807	18
34	Gastrointestinal pharmacology: practical tips for the esophagologist. <b>2020</b> , 1481, 90-107	6
33	Similarity and difference in the characteristics of eosinophilic esophagitis between Western countries and Japan. <b>2021</b> , 33, 708-719	2
32	Long-term Continued Proton Pump Inhibitor Use is Common in Patients Diagnosed with Eosinophilic Esophagitis Despite Failure of Histologic Response: Data from a two-centre study: Long-term PPI Use in Patients with EoE <b>2020</b> , 2, 281-287	
31	Targeted Therapies for Eosinophilic Gastrointestinal Disorders. <b>2020</b> , 34, 477-493	9
30	Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly. <b>2020</b> , 20, 39	3
29	Eosinophilic Esophagitis: Update on Diagnosis and Treatment in Pediatric Patients. <b>2020</b> , 22, 343-356	4
28	Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor non-responders compared with proton pump inhibitor responders of eosinophilic esophagitis. <b>2021</b> , 18, 362-371	О
27	From Allergy to Cancer-Clinical Usefulness of Eotaxins. <b>2021</b> , 13,	3
26	Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. <b>2021</b> , 19, 94-132	3

25	Searching for Noninvasive Predictors of the Diagnosis and Monitoring of Eosinophilic Esophagitis-The Importance of Biomarkers of the Inflammatory Reaction Involving Eosinophils. <b>2021</b> , 11,		1
24	Effectiveness of PPI treatment and guideline adherence in 236 patients with eosinophilic oesophagitis-Results from the population-based DanEoE cohort shows a low complication rate. <b>2021</b> , 9, 910-918		2
23	JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. <b>2016</b> , 11, e0157376		38
22	Eosinophilic esophagitis: Current concepts in diagnosis and treatment. <b>2019</b> , 25, 4598-4613		17
21	Eosinophilic esophagitis: From pathophysiology to treatment. <b>2015</b> , 6, 150-8		21
20	Eosinophilic Esophagitis: Incidence, Diagnosis, Management, and Future Directions. <b>2021</b> , 50, 825-841		1
19	The main statements of the European society of eosinophilic oesophagitis guidelines. 2018, 7, 65		1
18	Non-Barrett Esophagitis. <b>2021</b> , 33-53		
17	Proton Pump Inhibitor-Responsive Esophageal Eosinophilia. <b>2014</b> , 10, 739-741		
16	An Evolving Approach to the Diagnosis of Eosinophilic Esophagitis. <b>2018</b> , 14, 358-366		2
16 15	An Evolving Approach to the Diagnosis of Eosinophilic Esophagitis. <b>2018</b> , 14, 358-366  Evidence-based treatments for eosinophilic esophagitis: insights for the clinician <b>2022</b> , 15, 175628482	11068	
		211068 5.1	
15	Evidence-based treatments for eosinophilic esophagitis: insights for the clinician <b>2022</b> , 15, 175628482  Potential Mechanisms of Acupuncture for Functional Dyspepsia Based on Pathophysiology		6 <b>6</b> 5
15 14	Evidence-based treatments for eosinophilic esophagitis: insights for the clinician 2022, 15, 175628482  Potential Mechanisms of Acupuncture for Functional Dyspepsia Based on Pathophysiology  Frontiers in Neuroscience, 2021, 15, 781215  Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets	5.1	6 <b>6</b> 5
15 14 13	Evidence-based treatments for eosinophilic esophagitis: insights for the clinician 2022, 15, 175628482  Potential Mechanisms of Acupuncture for Functional Dyspepsia Based on Pathophysiology  Frontiers in Neuroscience, 2021, 15, 781215  Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets  Frontiers in Physiology, 2021, 12, 815842  Current options and investigational drugs for the treatment of eosinophilic esophagitis Expert	5.1 4.6	6 <b>6</b> 5 0
15 14 13	Evidence-based treatments for eosinophilic esophagitis: insights for the clinician 2022, 15, 175628482  Potential Mechanisms of Acupuncture for Functional Dyspepsia Based on Pathophysiology  Frontiers in Neuroscience, 2021, 15, 781215  Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets  Frontiers in Physiology, 2021, 12, 815842  Current options and investigational drugs for the treatment of eosinophilic esophagitis Expert Opinion on Investigational Drugs, 2022,  [New recommendations on the diagnosis and treatment of eosinophilic esophagitis in children and	5.1 4.6 5.9	6 <b>6</b> 5 0
15 14 13 12	Evidence-based treatments for eosinophilic esophagitis: insights for the clinician 2022, 15, 175628482  Potential Mechanisms of Acupuncture for Functional Dyspepsia Based on Pathophysiology  Frontiers in Neuroscience, 2021, 15, 781215  Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets  Frontiers in Physiology, 2021, 12, 815842  Current options and investigational drugs for the treatment of eosinophilic esophagitis Expert Opinion on Investigational Drugs, 2022,  [New recommendations on the diagnosis and treatment of eosinophilic esophagitis in children and adults]. Medycyna Wieku Rozwojowego, 2018, 22, 379-384  Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and	5.1 4.6 5.9	665 O 4

7	Drug treatment strategies for eosinophilic esophagitis in adults <i>Expert Opinion on Pharmacotherapy</i> , <b>2022</b> , 1-14	4	
6	Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective <i>Children</i> , <b>2021</b> , 8,	2.8	1
5	Acid-Lowering Drugs for the Treatment of Gastro-esophageal Reflux Disease. 2022, 273-305		
4	Exploring Treatment Options for Eosinophilic Esophagitis. <i>Gastroenterology Insights</i> , <b>2022</b> , 13, 228-237	2.1	
3	Current treatment options and long-term outcomes in patients with eosinophilic esophagitis. <i>Expert Review of Clinical Immunology</i> , 1-14	5.1	0
2	In Search of Biomarkers in Eosinophilic Oesophagitis: We Are Not There Yet!. 66-73		0
1	Assessment of Esophageal Motility in Patients With Eosinophilic Esophagitis. <b>2023</b> , 57, 10-30		0